Gabriella Orosz

Dr. Gabriella Orosz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KTKinga Tibori
Kinga Tibori
GOGabriella Orosz
Gabriella Orosz
VZVeronika Zámbó
Veronika Zámbó
PSPéter Szelényi
Péter Szelényi
FSFarkas Sarnyai
Farkas Sarnyai
Kereszturi ÉvaKereszturi Éva
Kereszturi Éva
Disturbances in lipid metabolism related to excessive food intake and sedentary lifestyle are among major risk of various metabolic disorders. Stearoyl-CoA desaturase-1 (SCD1) has an essential role in these diseases, as it catalyzes the synthesis of unsaturated fatty acids, both supplying for fat storage and contributing to cellular defense against saturated fatty acid toxicity. Recent studies show that increased activity or over-expression of SCD1 is one of the contributing factors for type 2 diabetes mellitus (T2DM). We aimed to investigate the impact of the common missense rs2234970 (M224L) polymorphism on SCD1 function in transfected cells. We found a higher expression of the minor Leu224 variant, which can be attributed to a combination of mRNA and protein stabilization. The latter was further enhanced by various fatty acids. The increased level of Leu224 variant resulted in an elevated unsaturated: saturated fatty acid ratio, due to higher oleate and palmitoleate contents. Accumulation of Leu224 variant was found in a T2DM patient group, however, the difference was statistically not significant. In conclusion, the minor variant of rs2234970 polymorphism might contribute to the development of obesity-related metabolic disorders, including T2DM, through an increased intracellular level of SCD1.

3 October 2022 in Genes
Verified
Journal Article
Open access
PDF file
VZVeronika Zámbó
Veronika Zámbó
GOGabriella Orosz
Gabriella Orosz
LSLuca Szabó
Luca Szabó
KTKinga Tibori
Kinga Tibori
SSSzabolcs Sipeki
Szabolcs Sipeki
Kereszturi ÉvaKereszturi Éva
Kereszturi Éva
The combined prevalence of type 1 (T1DM) and type 2 (T2DM) diabetes mellitus is 10.5% worldwide and this is constantly increasing. The pathophysiology of the diseases include disturbances of the lipid metabolism, in which acyl-CoA desaturases play a central role as they synthesize unsaturated fatty acids, thereby providing protection against lipotoxicity. The stearoyl-CoA desaturase-5 (SCD5) isoform has received little scientific attention. We aimed to investigate the SCD5 promoter and its polymorphisms in vitro, in silico and in a case-control study. The SCD5 promoter region was determined by a luciferase reporter system in HepG2, HEK293T and SK-N-FI cells and it was proved to be cell type-specific, but it was insensitive to different fatty acids. The effect of the SCD5 promoter polymorphisms rs6841081 and rs3811792 was tested in the transfected cells. The T allele of rs3811792 single nucleotide polymorphism (SNP) significantly reduced the activity of the SCD5 promoter in vitro and modified several transcription factor binding sites in silico. A statistically significant association of rs3811792 SNP with T1DM and T2DM was also found, thus supporting the medical relevance of this variation and the complexity of the molecular mechanisms in the development of metabolic disorders. In conclusion, the minor allele of rs3811792 polymorphism might contribute to the development of diabetes by influencing the SCD5 promoter activity.

Verified
Journal Article
Open access
PDF file
GOGabriella Orosz
Gabriella Orosz
LSLuca Szabó
Luca Szabó
SBSzanna Bereti
Szanna Bereti
VZVeronika Zámbó
Veronika Zámbó
MCMiklós Csala
Miklós Csala
Kereszturi ÉvaKereszturi Éva
Kereszturi Éva
Alternative splicing (AS) is a major means of post-transcriptional control of gene expression, and provides a dynamic versatility of protein isoforms. Cancer-related AS disorders have diagnostic, prognostic and therapeutic values. Changes in the expression and AS of human stearoyl-CoA desaturase-5 (SCD5) are promising specific tumor markers, although the transcript variants (TVs) of the gene have not yet been confirmed. Our in silico, in vitro and in vivo study focuses on the distribution of SCD5 TVs (A and B) in human tissues, the functionality of the relevant splice sites, and their modulation by certain single-nucleotide variations (SNVs). An order of magnitude higher SCD5A expression was found compared with SCD5B. This unequal splicing is attributed to a weaker recognition of the SCD5B-specific splicing acceptor site, based on predictions confirmed by an optimized minigene assay. The pronounced dominance of SCD5A was largely modified (rs1430176385_A, rs1011850309_A) or even inverted (rs1011850309_C) by natural SNVs at the TV-specific splice sites. Our results provide long missing data on the proportion of SCD5 TVs in human tissues and reveal mutation-driven changes in SCD5 AS, potentially affecting tumor-associated reprogramming of lipid metabolism, thus having prognostic significance, which may be utilized for novel and personalized therapeutic approaches.

12 June 2026 in Journal of Lipid Research
Verified
Journal Article
Open access
VZVeronika Zámbó
Veronika Zámbó
GOGabriella Orosz
Gabriella Orosz
MCMiklós Csala
Miklós Csala
Kereszturi ÉvaKereszturi Éva
Kereszturi Éva
Stearoyl-CoA desaturase (SCD) forms double bonds at the Δ9 position of saturated acyl-CoAs, primarily palmitoyl-CoA and stearoyl-CoA. Of the two human isoforms, SCD1 is ubiquitous, while the tissue-specific SCD5 is expressed in the brain, pancreas, and reproductive tissues, where it facilitates local lipid remodeling and modulates cellular signaling in a context-dependent manner. Its activity significantly impacts membrane composition, vesicular trafficking, and post-translational processing of Wnt proteins, thereby influencing cell fate and signal transduction pathways like EGFR and Akt. The multifaceted regulation of SCD5 involves transcriptional activation by SREBP1 and EGR2, as well as repression by HIF2α and NME2. Post-transcriptional modulation includes alternative splicing, which yields SCD5A and SCD5B variants, and the inhibitory actions of specific microRNAs, such as miR-221/222 and miR-145-5p. Notably, the SCD5 protein lacks the N-terminal PEST degradation motifs characteristic of SCD1, which contributes to its distinct stability profile across different cell types. SCD5 plays context-dependent roles in various human cancers. While its downregulation in melanoma and breast cancer is associated with advanced malignancy and epithelial-to-mesenchymal transition (EMT), its expression in glioblastoma stem-like cells is essential for survival and DNA repair. Beyond cancer, genetic polymorphisms and expression alterations of SCD5 have been linked to neurodegenerative diseases, psychiatric conditions like schizophrenia, and metabolic dysfunctions such as visceral adiposity and type 2 diabetes. Understanding these tissue-specific regulatory milieus is crucial for developing SCD5-targeted therapeutic strategies. Here, we review available knowledge regarding the structure, regulation, and function of SCD5, with focus on its role in cell signaling and disease.